Retatrutide: Potential Availability and Impact on Weight Loss Treatment | Retatrutide News

Retatrutide is a GLP-1 agonist under development by Eli Lilly for weight loss. Its potential availability could impact obesity treatment options.
Market News · October 23, 2026